These results on the failure of imatinib to eradicate CML in Sca1-BCR-ABLp210 mice have been later confirmed in human patients [39,40,41,42,43], and this is a clear example of how a good preclinical model can anticipate the human CSC-therapeutic response. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.